Akebia Therapeutics (AKBA) News Today $1.87 +0.03 (+1.63%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18 at 8:00 AM | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.December 13, 2024 | marketbeat.comAkebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trialDecember 3, 2024 | markets.businessinsider.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisDecember 3, 2024 | prnewswire.comAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 25, 2024 | prnewswire.comQ3 2024 Earnings: Hold Akebia TherapeuticsNovember 20, 2024 | seekingalpha.comPiper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)November 14, 2024 | markets.businessinsider.comVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseaseNovember 14, 2024 | prnewswire.comAkebia Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | prnewswire.comAkebia Therapeutics Prepares for Vafseo LaunchNovember 10, 2024 | markets.businessinsider.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50November 10, 2024 | finance.yahoo.comAkebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...November 8, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comAkebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | prnewswire.comAkebia Q3 2024 Earnings PreviewNovember 6, 2024 | msn.comAkebia Therapeutics (AKBA) Set to Announce Earnings on ThursdayAkebia Therapeutics (NASDAQ:AKBA) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comAkebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business HighlightsNovember 1, 2024 | prnewswire.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in OctoberAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 17,680,000 shares, a decline of 6.0% from the September 30th total of 18,800,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is presently 10.6 days.October 31, 2024 | marketbeat.comAkebia Therapeutics: Strategic Developments and Financial Outlook Drive Buy RatingOctober 23, 2024 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research report on Wednesday.October 23, 2024 | marketbeat.comAkebia signs commercial supply contract with dialysis organizationOctober 22, 2024 | markets.businessinsider.comAkebia Therapeutics Secures Supply Agreement for VafseoOctober 22, 2024 | markets.businessinsider.comAkebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on DialysisOctober 22, 2024 | prnewswire.comAkebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024October 15, 2024 | prnewswire.comMarshall Wace LLP Reduces Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA)Marshall Wace LLP lessened its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 75.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 247,069 shares of the biopharmaceutical company's stock afOctober 12, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Stock, Insider Trading ActivityOctober 10, 2024 | benzinga.comAkebia Therapeutics (NASDAQ:AKBA) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.comAkebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...October 10, 2024 | finance.yahoo.comCMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025October 10, 2024 | prnewswire.comBuy Rating on Akebia Therapeutics: Strong Market Penetration Prospects for VafseoOctober 9, 2024 | markets.businessinsider.comAkebia, U.S. Renal Care Enter Supply Contract; USRC Physicians To Prescribe VafseoOctober 7, 2024 | markets.businessinsider.comAkebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on DialysisOctober 7, 2024 | prnewswire.comAkebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To ProfitabilityOctober 5, 2024 | finance.yahoo.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2024 | prnewswire.comAlerce Investment Management L.P. Has $5.86 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA)Alerce Investment Management L.P. lessened its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 56.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,747,906September 25, 2024 | marketbeat.comBank of New York Mellon Corp Boosts Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA)Bank of New York Mellon Corp boosted its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 3,122.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 604,551 shares of the bioSeptember 24, 2024 | marketbeat.comAcadian Asset Management LLC Sells 1,246,372 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA)Acadian Asset Management LLC cut its stake in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 23.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,063,383 shares of the bioSeptember 13, 2024 | marketbeat.comBuy Rating Reaffirmed for Akebia Therapeutics Ahead of Vafseo’s Market LaunchSeptember 7, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA)HC Wainwright restated a "buy" rating and set a $7.50 price target on shares of Akebia Therapeutics in a research note on Friday.September 6, 2024 | marketbeat.comAkebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on DialysisSeptember 5, 2024 | prnewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | prnewswire.comAkebia Therapeutics to Present at Upcoming Investor ConferencesAugust 26, 2024 | prnewswire.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. cut its holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 73.2% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 211,647 shares of the biopharmaceutical company's stock after selling 578,836 shares during theAugust 25, 2024 | marketbeat.comZacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and AkebiaAugust 19, 2024 | finance.yahoo.comHC Wainwright Weighs in on Akebia Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:AKBA)Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their Q3 2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a note issued to investors on Monday, August 12th. HC Wainwright analyst E. Arce expects that the biopharmaceutAugust 14, 2024 | marketbeat.comOcuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate UpdateAugust 13, 2024 | markets.businessinsider.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. lifted its holdings in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 8.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,225,972 shares of the biopharmAugust 13, 2024 | marketbeat.comAkebia Therapeutics, Inc. (AKBA) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.com Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen. I urge you to watch this video now. AKBA Media Mentions By Week AKBA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.300.69▲Average Medical News Sentiment AKBA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼22▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News NRIX News RCUS News KNSA News IMCR News OCUL News MESO News TVTX News NTLA News PRAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts